Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes

This study has been completed.
Information provided by:
Walter Reed Army Medical Center
ClinicalTrials.gov Identifier:
First received: December 19, 2006
Last updated: NA
Last verified: December 2006
History: No changes posted
The objective of this study is to evaluate the effect of brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) on pupil diameter under different luminance conditions.

Condition Intervention
Drug: Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P)

Study Type: Observational
Study Design: Time Perspective: Longitudinal

Resource links provided by NLM:

Further study details as provided by Walter Reed Army Medical Center:

Estimated Enrollment: 20

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Adult active duty personnel between 18 and 50 years of age with best corrected visual acuity of 20/20 or better.

Exclusion Criteria:

  • Patients not meeting above stated age criteria
  • Females that are pregnant or lactating (non pregnant females of childbearing potential will have pregnancy test prior to participating in study)
  • History of serious ocular, neurological, cardiovascular disease
  • History of severe systemic disease
  • History of arrhythmias or high blood pressure
  • Patients currently taking any type of ocular or systemic medications except multivitamins.
  • Patients with abnormal pupil shape, Addie's pupil, anisocoria, or abnormal pupil defect.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00413751

United States, District of Columbia
Walter Reed Army Medical Center
Washington, District of Columbia, United States, 20307
Sponsors and Collaborators
Walter Reed Army Medical Center
Principal Investigator: KRAIG S. BOWER, MD Walter Reed Army Medical Center
  More Information

ClinicalTrials.gov Identifier: NCT00413751     History of Changes
Other Study ID Numbers: WRAMC WU #03-23004 
Study First Received: December 19, 2006
Last Updated: December 19, 2006
Health Authority: United States: Federal Government

Keywords provided by Walter Reed Army Medical Center:
Large pupils rendering night vision difficulties such as haloes, glare, and monocular diplopia

Additional relevant MeSH terms:
Brimonidine Tartrate
Ophthalmic Solutions
Adrenergic Agents
Adrenergic Agonists
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Antihypertensive Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmaceutical Solutions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 22, 2016